
BDX Stock Forecast & Price Target
BDX Analyst Ratings
Bulls say
Becton Dickinson is poised for long-term growth and is an attractive investment opportunity in the medical technology sector. Becton Dickinson's recent spinoff of its Lifesciences business allows for a sharpened focus on high-growth MedTech markets, driving projected mid-single digit growth. The company is committed to returning cash to shareholders through repurchases, and recent deals will positively impact its stock price. With strong sales and key launches planned, including the HemoSphere Stream Module and BD Pyxis Pro, BD is well-positioned for revenue growth and has a strong pipeline for potential acquisitions. However, the company may face risks and challenges in meeting its financial targets and achieving separation in the future. Overall, BD presents a solid investment opportunity in the medical technology sector with its strong financial performance and dedication to driving shareholder returns.
Bears say
Becton Dickinson is well-positioned to deliver high single-digit average EPS growth through FY2030 due to its strategic execution and focus on cost-efficiency initiatives. The company's strong cash distribution, ongoing dividends and share repurchases, and potential upside from the Waters Corporation merger and concentrated investments in high-growth markets further support a positive outlook. However, the potential impact of tariff uncertainty on the company's supply chain processes and its ongoing debt paydown should be monitored closely.
This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.
BDX Analyst Forecast & Price Prediction
Start investing in BDX
Order type
Buy in
Order amount
Est. shares
0 shares